Two of the biggest names in GLP-1 medicine were accused of using their market power to make life harder for compounding pharmacies. In January 2026, Strive Specialties, a compounding pharmacy, filed an antitrust lawsuit against Eli Lilly and Novo Nordisk, alleging that the pharmaceutical companies had engaged in a coordinated effort to restrict competition from compounded GLP-1 medications. The allegations touched everything from telehealth agreements and payment processors to technology platforms and public statements about compounded drugs. But there is an important update that changes the legal status of the entire story. On August 3, 2026, a federal judge in the Western District of Texas dismissed Strive's antitrust claims with prejudice. The court concluded that Strive had failed to plausibly establish the relevant market necessary for its antitrust claims and also found problems with its theory of antitrust injury. That means the allegations should not be presented as proven misconduct. But the case is still worth examining because it highlights one of the most important battles surrounding the GLP-1 market: who gets to compete, at what price, and under what rules? What Strive Alleged Strive's lawsuit argued that Eli Lilly and Novo Nordisk were not simply competing with compounding pharmacies on price, availability, or product offerings. Instead, Strive alleged that the pharmaceutical companies had taken steps to restrict the channels through which compounded GLP-1 products could reach patients. According to the complaint, those allegations included relationships with telehealth providers, restrictions involving payment and technology platforms, and public messaging about compounded medications. Strive argued that these actions collectively limited its ability to compete in the GLP-1 market. The complaint also pointed to statements and communications surrounding compounded GLP-1 products. Strive alleged that Lilly had characterized compounded medications as risky, unproven, fake, or counterfeit and argued that such messaging could discourage physicians and patients from considering compounded alternatives.

Every time a new peptide vendor appears, the conversation usually goes the same way: “Has anyone used them?” “Are they legit?” “Can someone send me a source?” Those questions are understandable, but they are not particularly useful. A vendor can have hundreds of positive comments and still provide poor documentation. Another company might have very few reviews simply because it is new. And recommendations can be complicated by affiliate relationships, discount codes, or people repeating information they have never independently verified. Instead of trying to maintain a constantly changing list of “good” and “bad” vendors, it makes more sense to have a repeatable verification process. The goal isn't to prove that a supplier is perfect. The goal is to eliminate as much uncertainty as possible before accepting a research material into your laboratory. Here are nine checks that can help. A big thank you to Orion Peptides for supporting my research and helping make this content possible. If you’re looking for a research-focused peptide supplier, you can check them out and use my code Parker15 for a 15% discount on your order. 1. Start With the COA — But Look Beyond the Big Purity Number The first thing I want to see is a batch-specific Certificate of Analysis (COA). Not simply: “All products are independently tested.” Not: “COAs available upon request.” And definitely not a graphic on a product page saying 99% PURE. A useful COA should connect a specific product to a specific production batch and provide enough information to understand what was actually tested. Look for: - Product name - Batch or lot number - Testing date - Laboratory identification - Analytical methods - Results - Relevant specifications - Actual analytical data where applicable The most important distinction is that a COA is evidence, not a guarantee. A professional-looking PDF can still be inaccurate, incomplete, outdated, or fabricated.

A Certificate of Analysis can look incredibly convincing. A professional logo. A laboratory name. A purity figure of 99%. A signature at the bottom. But none of those things, individually, prove that the document is genuine—or that it actually relates to the vial you have in front of you. For anyone sourcing peptides for legitimate laboratory research, the COA is one of the most useful quality-control documents available. It can also be one of the easiest documents to manipulate, recycle, or misunderstand. The important question isn't: “Does this supplier have a COA?” It is: “Does this COA provide credible, traceable evidence about this specific batch?” That distinction changes everything. Why COAs Matter A COA is intended to document analytical testing performed on a particular material or batch. A useful report should allow you to answer several basic questions: - What material was tested? - Which batch was tested? - When was it tested? - Which laboratory performed the analysis? - What analytical methods were used? - What were the actual results? - Can the report be independently verified? If a document cannot answer those questions, its value as quality evidence is limited. And remember: a COA is evidence, not a guarantee. Even a genuine report only tells you what was tested and what the reported results showed. It does not automatically establish that every product sold by that supplier has the same characteristics. 1. Start With the Batch Number This is probably the easiest check—and one of the most frequently overlooked. Look at the batch or lot number printed on the product documentation and compare it with the batch number associated with the COA. They should correspond. If a supplier provides one generic COA for multiple batches, you have to ask an obvious question: Was this exact batch actually tested? A legitimate quality system should provide traceability between the analytical report and the material being supplied.

If you spend enough time around the online peptide industry, you eventually run into some eye-catching numbers. $40,000 a week. $60,000 a week in profit. $100,000 a month in sales after 90 days. $500,000–$1 million a month. And, according to one Reddit commenter, the biggest companies are doing $5 million a month. So the obvious question is: How much are people actually making selling peptides? The honest answer is: nobody outside the businesses themselves can verify most of these numbers. But that doesn't mean the opportunity isn't real. There is clearly significant money flowing through the peptide ecosystem. The challenge is separating genuine business revenue from Reddit screenshots, anonymous claims, gross sales, profit, and businesses operating in regulatory grey areas. And once you start looking at the numbers properly, the story becomes much more interesting. The $40,000-a-week peptide business One Reddit entrepreneur thread provides a fascinating example. A commenter claimed that a friend had started selling peptides online only a few months earlier and was already making approximately: $40,000 per week. Later in the discussion, the same person claimed the business had reached approximately: $60,000 per week in profit. The business was described as a solo ecommerce operation supplying "researchers." The interesting part wasn't just the revenue claim. It was the explanation of how the business generated its traffic. According to the commenter, the company operated two TikTok accounts — one personal and one business account. A few videos went viral and directed viewers to the company's website. From there, the claim was that the company needed only around 15+ orders per day to maintain approximately $30,000–$40,000 in weekly sales. That immediately gives us something useful to work with. The mathematics Suppose a business receives: - 15 orders per day - 7 days per week - 105 orders per week - $350 average order value That's approximately:

For years, MOTS-c has primarily been discussed in the context of metabolism, exercise, insulin sensitivity, cellular stress, and mitochondrial signaling. A new study published in eLife on August 18, 2026, adds a completely different dimension to the story. Researchers report evidence that MOTS-c may function as a mitochondrial-encoded host-defense peptide, with direct antibacterial activity and immunomodulatory effects. The finding raises an intriguing question: Could mitochondria do more than regulate cellular energy? Could they also participate directly in immune defense? What Is MOTS-c? MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Unlike many signaling peptides encoded by nuclear DNA, MOTS-c is encoded within the human mitochondrial genome. It has attracted significant research interest because of its reported involvement in metabolic regulation, cellular stress responses, and mitochondrial signaling. The new eLife research suggests that its biological role may extend into another fundamental area: host defense. MOTS-c Showed Direct Antibacterial Activity The researchers first investigated whether MOTS-c could interact directly with bacteria. Their experiments included Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). The researchers found that MOTS-c interacted with bacterial cells and promoted bacterial aggregation. They also identified structural features of MOTS-c that appear important for this activity, including hydrophobic and positively charged regions. The proposed mechanism is consistent with how other host-defense peptides can interact with bacterial membranes. In other words, MOTS-c wasn't simply being studied as a metabolic signaling molecule. Researchers were observing behavior associated with antimicrobial peptides. Then Researchers Took the Study Into Mice The next question was whether these antibacterial effects could translate into an animal model. Researchers used an acute peritonitis model involving MRSA in mice.